• Mashup Score: 57
    THE ONCOALERT NETWORK - 13 day(s) ago

    ​Welcome to OncoAlert ​

    Tweet Tweets with this article
    • The @OncoAlert 🚨Newsletter for #GU25 🇺🇸 COMES OUT ON WEDNESDAY FEB19, 2025 REGISTER AT https://t.co/1s3pztO6Vs OR https://t.co/dq8GEzl9ps ⭐️TALAPRO2 ⭐️ENZA-P ⭐️ARASENS ⭐️ARANOTE ⭐️LIBERTAS ⭐️STAMPEDE🐂 ⭐️EPIC-A ⭐️NIAGARA🌊 ⭐️EV-304 ⭐️CheckMate-9ER ♟️ ⭐️COSMIC-313☄️… https://t.co/HUVxP3kA9G https://t.co/drg8Wa5oN4

  • Mashup Score: 57
    THE ONCOALERT NETWORK - 15 day(s) ago

    ​Welcome to OncoAlert ​

    Tweet Tweets with this article
    • The @OncoAlert 🚨Newsletter for #GU25 🇺🇸 COMES OUT ON WEDNESDAY FEB19, 2025 REGISTER AT https://t.co/1s3pztO6Vs OR https://t.co/dq8GEzl9ps ⭐️TALAPRO2 ⭐️ENZA-P ⭐️ARASENS ⭐️ARANOTE ⭐️LIBERTAS ⭐️STAMPEDE🐂 ⭐️EPIC-A ⭐️NIAGARA🌊 ⭐️EV-304 ⭐️CheckMate-9ER ♟️ ⭐️COSMIC-313☄️… https://t.co/HUVxP3kA9G https://t.co/drg8Wa5oN4

  • Mashup Score: 57
    THE ONCOALERT NETWORK - 15 day(s) ago

    ​Welcome to OncoAlert ​

    Tweet Tweets with this article
    • The @OncoAlert 🚨Newsletter for #GU25 🇺🇸 COMES OUT ON WEDNESDAY FEB19, 2025 REGISTER AT https://t.co/1s3pztO6Vs OR https://t.co/dq8GEzl9ps ⭐️TALAPRO2 ⭐️ENZA-P ⭐️ARASENS ⭐️ARANOTE ⭐️LIBERTAS ⭐️STAMPEDE🐂 ⭐️EPIC-A ⭐️NIAGARA🌊 ⭐️EV-304 ⭐️CheckMate-9ER ♟️ ⭐️COSMIC-313☄️… https://t.co/HUVxP3kA9G https://t.co/drg8Wa5oN4

  • Mashup Score: 6

    PURPOSEPrognostic staging after neoadjuvant chemotherapy (NACT) is not included in American Joint Commission on Cancer (AJCC) staging. This study addressed this deficiency by including responses to therapy with standardized staging variables in a …

    Tweet Tweets with this article
    • RT @mirrorsmed: Novel Postneoadjuvant Prognostic #BreastCancer Staging System https://t.co/JF1GKouuXA Study developed and validated a nov…

  • Mashup Score: 21
    OncoAlert - 15 day(s) ago

    Medicin · Varje dag · The latest in Oncology News, happenings and research. 

    Tweet Tweets with this article
    • The @OncoAlert 🚨Podcast👇👇👇 https://t.co/GxpPvQ37OO Sign Up via @ApplePodcasts 🍏 Hosts @ElisaAgostinett 🇧🇪on #BreastCancer @BiagioRicciutMD 🇺🇸on #LungCancer @realbowtiedoc 🇺🇸on #GI & #SupportiveCare @NiuSanford 🇺🇸on #RadOnc @bavilima 🇧🇷on #GU oncology @weoncologists 🇺🇸 on https://t.co/t0sIhBCAL9

  • Mashup Score: 21
    OncoAlert - 15 day(s) ago

    Medicin · Varje dag · The latest in Oncology News, happenings and research. 

    Tweet Tweets with this article
    • The @OncoAlert 🚨Podcast👇👇👇 https://t.co/GxpPvQ37OO Sign Up via @ApplePodcasts 🍏 Hosts @ElisaAgostinett 🇧🇪on #BreastCancer @BiagioRicciutMD 🇺🇸on #LungCancer @realbowtiedoc 🇺🇸on #GI & #SupportiveCare @NiuSanford 🇺🇸on #RadOnc @bavilima 🇧🇷on #GU oncology @weoncologists 🇺🇸 on https://t.co/t0sIhBCAL9

  • Mashup Score: 5

    Circulating tumor DNA (ctDNA) is a promising non-invasive tool that has been demonstrated to be a clinically useful biomarker in several tumor types for risk stratification, prognosis, and early detection of recurrence. However, there are limited data on the clinical utility of ctDNA in endometrial cancer (EC) compared with other solid tumors. The evolution of EC management through the integration of molecular characterization into the treatment algorithm has intensified the need to develop more effective predictive biomarkers to optimize treatment and reduce clinical toxicities.

    Tweet Tweets with this article
    • RT @IJGConline: ctDNA in #endometrialcancer: clinical significance and implications @IlariaCapasso12 🧬 https://t.co/Yz3gkjzZZI @pedrorami…

  • Mashup Score: 57
    THE ONCOALERT NETWORK - 18 day(s) ago

    ​Welcome to OncoAlert ​

    Tweet Tweets with this article
    • The @OncoAlert 🚨Newsletter for #GU25 🇺🇸 COMES OUT ON WEDNESDAY FEB19, 2025 REGISTER AT https://t.co/1s3pztO6Vs OR https://t.co/dq8GEzl9ps ⭐️TALAPRO2 ⭐️ENZA-P ⭐️ARASENS ⭐️ARANOTE ⭐️LIBERTAS ⭐️STAMPEDE🐂 ⭐️EPIC-A ⭐️NIAGARA🌊 ⭐️EV-304 ⭐️CheckMate-9ER ♟️ ⭐️COSMIC-313☄️… https://t.co/HUVxP3kA9G https://t.co/drg8Wa5oN4